{"id":36952,"date":"2026-06-06T09:06:00","date_gmt":"2026-06-06T03:36:00","guid":{"rendered":"https:\/\/atsixty.com\/?p=36952"},"modified":"2026-06-06T09:06:29","modified_gmt":"2026-06-06T03:36:29","slug":"crystal-arthropathies","status":"publish","type":"post","link":"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/","title":{"rendered":"Crystal Arthropathies"},"content":{"rendered":"\n\n\n<meta charset=\"UTF-8\">\n<meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0\">\n<title>Morning Rounds \u00b7 Crystal Arthropathies<\/title>\n<link href=\"https:\/\/fonts.googleapis.com\/css2?family=Playfair+Display:ital,wght@0,400;0,600;0,700;1,400;1,600&#038;family=Source+Serif+4:ital,wght@0,300;0,400;0,600;1,400&#038;display=swap\" rel=\"stylesheet\">\n<style>\n#rhmq04 *,#rhmq04 *::before,#rhmq04 *::after{box-sizing:border-box;margin:0;padding:0}\n#rhmq04{\n  --ter:#8B3D20;\n  --ter-light:#B85A38;\n  --ter-pale:#FDF0EB;\n  --ter-dark:#6B2D14;\n  --correct:#2D6B47;--correct-bg:#EAF6EF;--correct-border:#3A9960;\n  --wrong:#B83232;--wrong-bg:#FDF0F0;--wrong-border:#E53935;\n  --ink:#2C1810;--ink-mid:#5A3D30;--ink-soft:#9A7060;\n  --line:#E8DDD8;--cream:#FAF6F2;--warm:#FFFDF9;\n  font-family:'Source Serif 4',Georgia,serif;\n  font-size:16px;color:var(--ink);background:var(--cream);\n  line-height:1.7;padding:0 0 64px;\n}\n#rhmq04 .mr-header{background:var(--ter);color:#FFFDF9;padding:34px 24px 28px;text-align:center}\n#rhmq04 .mr-eyebrow{font-size:0.68rem;letter-spacing:0.18em;text-transform:uppercase;font-weight:600;opacity:0.65;margin-bottom:10px}\n#rhmq04 .mr-title{font-family:'Playfair Display',serif;font-size:1.75rem;font-weight:700;line-height:1.2;margin-bottom:4px}\n#rhmq04 .mr-title em{font-style:italic;font-weight:400;opacity:0.88}\n#rhmq04 .mr-subtitle{font-size:0.82rem;opacity:0.7;margin-top:8px;font-style:italic}\n#rhmq04 .mr-chips{display:flex;justify-content:center;gap:10px;margin-top:18px;flex-wrap:wrap}\n#rhmq04 .mr-chip{background:rgba(255,255,255,0.13);border:1px solid rgba(255,255,255,0.22);border-radius:20px;padding:4px 13px;font-size:0.73rem}\n#rhmq04 .mr-sentinel{height:1px}\n#rhmq04 .mr-progress{position:fixed;top:0;left:0;right:0;z-index:9999;background:var(--warm);border-bottom:1px solid var(--line);box-shadow:0 2px 12px rgba(44,24,16,0.08);padding:9px 16px;display:none}\n#rhmq04 .mr-progress.visible{display:block}\n#rhmq04 .mr-prog-inner{max-width:720px;margin:0 auto;display:flex;align-items:center;justify-content:center}\n#rhmq04 .mr-pips{display:flex;align-items:center;justify-content:center}\n#rhmq04 .mr-pip-wrap{display:flex;align-items:center}\n#rhmq04 .mr-pip-line{width:28px;height:2px;background:var(--line);transition:background 0.35s}\n#rhmq04 .mr-pip-line.done{background:var(--ter)}\n#rhmq04 .mr-pip{width:28px;height:28px;border-radius:50%;border:2px solid var(--line);background:var(--warm);display:flex;align-items:center;justify-content:center;font-size:0.63rem;font-weight:700;color:var(--ink-soft);transition:all 0.3s;flex-shrink:0}\n#rhmq04 .mr-pip.correct{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#rhmq04 .mr-pip.wrong{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#rhmq04 .mr-body{max-width:720px;margin:0 auto;padding:0 16px}\n#rhmq04 .mr-case{background:var(--warm);border:1px solid var(--line);border-left:4px solid var(--ter);border-radius:10px;margin:28px 0;overflow:hidden;box-shadow:0 1px 6px rgba(44,24,16,0.05)}\n#rhmq04 .mr-case-top{padding:16px 20px 14px;display:flex;gap:14px;align-items:flex-start}\n#rhmq04 .mr-num{font-family:'Playfair Display',serif;font-size:2.2rem;font-weight:700;color:var(--ter);opacity:0.16;line-height:1;margin-top:-2px;flex-shrink:0}\n#rhmq04 .mr-meta{flex:1}\n#rhmq04 .mr-tag-row{display:flex;align-items:center;justify-content:space-between;margin-bottom:5px}\n#rhmq04 .mr-tag{font-size:0.61rem;font-weight:700;letter-spacing:0.14em;text-transform:uppercase;color:var(--ter);opacity:0.8}\n#rhmq04 .mr-diff{font-size:0.61rem;font-weight:700;letter-spacing:0.10em;text-transform:uppercase;color:var(--ink-soft)}\n#rhmq04 .mr-stem{font-size:0.94rem;color:var(--ink);line-height:1.72}\n#rhmq04 .mr-stem strong{font-weight:600}\n#rhmq04 .mr-stem em{font-style:italic}\n#rhmq04 .mr-rule{height:1px;background:var(--line);margin:0 20px}\n#rhmq04 .mr-opts{padding:12px 20px 16px;display:flex;flex-direction:column;gap:8px}\n#rhmq04 .mr-opt{display:flex;align-items:flex-start;gap:11px;padding:10px 14px;border:1.5px solid var(--line);border-radius:8px;cursor:pointer;background:var(--warm);transition:border-color 0.15s,background 0.15s;-webkit-tap-highlight-color:transparent}\n#rhmq04 .mr-opt:hover{border-color:var(--ter);background:var(--ter-pale)}\n#rhmq04 .mr-opt.locked{cursor:default}\n#rhmq04 .mr-opt.locked:hover{border-color:var(--line);background:var(--warm)}\n#rhmq04 .mr-opt.correct{border-color:var(--correct-border);background:var(--correct-bg);cursor:default}\n#rhmq04 .mr-opt.correct:hover{border-color:var(--correct-border);background:var(--correct-bg)}\n#rhmq04 .mr-opt.wrong{border-color:var(--wrong-border);background:var(--wrong-bg);cursor:default}\n#rhmq04 .mr-opt.wrong:hover{border-color:var(--wrong-border);background:var(--wrong-bg)}\n#rhmq04 .mr-opt.dimmed{opacity:0.35;cursor:default}\n#rhmq04 .mr-opt.dimmed:hover{border-color:var(--line);background:var(--warm)}\n#rhmq04 .mr-ltr{flex-shrink:0;width:20px;height:20px;border-radius:50%;border:1.5px solid var(--line);display:flex;align-items:center;justify-content:center;font-size:0.62rem;font-weight:700;color:var(--ink-soft);margin-top:2px;transition:all 0.15s}\n#rhmq04 .mr-opt.correct .mr-ltr{background:var(--correct-border);border-color:var(--correct-border);color:#fff}\n#rhmq04 .mr-opt.wrong .mr-ltr{background:var(--wrong-border);border-color:var(--wrong-border);color:#fff}\n#rhmq04 .mr-opt-text{font-size:0.9rem;color:var(--ink-mid);line-height:1.58}\n#rhmq04 .mr-opt.correct .mr-opt-text{color:var(--correct);font-weight:600}\n#rhmq04 .mr-opt.wrong .mr-opt-text{color:var(--wrong)}\n#rhmq04 .mr-exp{display:none;border-top:1px solid #c8e0d8;background:linear-gradient(180deg,#edf7f4 0%,#f4faf8 100%);padding:13px 20px 15px}\n#rhmq04 .mr-exp-lbl{font-size:0.61rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:var(--correct);margin-bottom:6px}\n#rhmq04 .mr-exp-text{font-size:0.86rem;color:#1c4a3a;line-height:1.68}\n#rhmq04 .mr-exp-text strong{font-weight:600}\n#rhmq04 .mr-exp-text em{font-style:italic}\n#rhmq04 .mr-exp-extra{margin-top:11px;padding-top:10px;border-top:1px dashed #9ACCC4;font-size:0.84rem;color:#1c4a3a;line-height:1.66}\n#rhmq04 .mr-exp-extra-lbl{font-size:0.59rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;color:var(--ter);margin-bottom:4px;display:block}\n#rhmq04 .mr-exp-extra strong{font-weight:600}\n#rhmq04 .mr-exp-extra em{font-style:italic}\n#rhmq04 .mr-img-wrap{margin-top:14px;background:var(--warm);border:1px solid var(--line);border-radius:8px;padding:14px;text-align:center}\n#rhmq04 .mr-img-wrap figcaption{font-size:0.73rem;color:var(--ink-soft);font-style:italic;margin-top:8px;line-height:1.4}\n#rhmq04 .mr-submit-wrap{text-align:center;padding:28px 16px 8px}\n#rhmq04 .mr-btn{background:var(--ter);color:#FFFDF9;border:none;border-radius:8px;padding:13px 44px;font-family:'Playfair Display',serif;font-size:1rem;font-weight:700;cursor:pointer;box-shadow:0 2px 8px rgba(139,61,32,0.28)}\n#rhmq04 .mr-btn:hover{background:var(--ter-dark)}\n#rhmq04 .mr-score{display:none;background:var(--warm);border:1px solid var(--line);border-top:4px solid var(--ter);border-radius:10px;margin:24px 0 0;box-shadow:0 2px 12px rgba(44,24,16,0.08);overflow:hidden}\n#rhmq04 .mr-score-in{padding:28px 24px;text-align:center}\n#rhmq04 .mr-score-ey{font-size:0.66rem;letter-spacing:0.14em;text-transform:uppercase;color:var(--ink-soft);margin-bottom:12px;font-weight:600}\n#rhmq04 .mr-ring{width:98px;height:98px;border-radius:50%;background:conic-gradient(var(--ter) 0%,var(--line) 0%);display:flex;align-items:center;justify-content:center;margin:0 auto 16px;position:relative}\n#rhmq04 .mr-ring::before{content:'';position:absolute;width:76px;height:76px;border-radius:50%;background:var(--warm)}\n#rhmq04 .mr-ring-in{position:relative;display:flex;flex-direction:column;align-items:center;line-height:1.2}\n#rhmq04 .mr-ring-pct{font-family:'Playfair Display',serif;font-size:1.3rem;font-weight:700;color:var(--ter)}\n#rhmq04 .mr-ring-sub{font-size:0.54rem;color:var(--ink-soft);text-transform:uppercase;letter-spacing:0.06em}\n#rhmq04 .mr-score-title{font-family:'Playfair Display',serif;font-size:1.15rem;font-weight:700;color:var(--ink);margin-bottom:4px}\n#rhmq04 .mr-score-net{font-size:0.9rem;color:var(--ter);font-weight:600;margin-bottom:4px}\n#rhmq04 .mr-verdict{font-size:0.83rem;color:var(--ink-soft);font-style:italic;margin-bottom:18px;padding:0 12px}\n#rhmq04 .mr-bands{display:flex;justify-content:center;gap:10px;flex-wrap:wrap}\n#rhmq04 .mr-band{padding:5px 13px;border-radius:16px;font-size:0.78rem;font-weight:600}\n#rhmq04 .mr-band-c{background:var(--correct-bg);color:var(--correct)}\n#rhmq04 .mr-band-w{background:var(--wrong-bg);color:var(--wrong)}\n#rhmq04 .mr-band-s{background:var(--ter-pale);color:var(--ter)}\n#rhmq04 .mr-retry{display:block;margin:18px auto 4px;background:transparent;border:2px solid var(--ter);color:var(--ter);border-radius:8px;padding:9px 28px;font-family:'Playfair Display',serif;font-size:0.92rem;font-weight:700;cursor:pointer}\n#rhmq04 .mr-retry:hover{background:var(--ter);color:#FFFDF9}\n@media(max-width:480px){#rhmq04 .mr-title{font-size:1.4rem}#rhmq04 .mr-num{font-size:1.7rem}#rhmq04 .mr-stem{font-size:0.9rem}#rhmq04 .mr-opt-text{font-size:0.86rem}}\n<\/style>\n\n<!-- Gout stages timeline SVG for Q2 debrief -->\n<div id=\"rhmq04-img1\" style=\"display:none\">\n  <figure class=\"mr-img-wrap\">\n    <svg viewBox=\"0 0 540 130\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" style=\"width:100%;max-width:540px;display:block;margin:0 auto\">\n      <rect x=\"0\" y=\"0\" width=\"540\" height=\"130\" rx=\"8\" fill=\"#F4F8F6\"\/>\n      <!-- Spine line -->\n      <line x1=\"30\" y1=\"65\" x2=\"510\" y2=\"65\" stroke=\"#C8D8D4\" stroke-width=\"2\"\/>\n      <!-- Stage 1 -->\n      <circle cx=\"80\" cy=\"65\" r=\"22\" fill=\"#3D5A80\" opacity=\"0.85\"\/>\n      <text x=\"80\" y=\"61\" text-anchor=\"middle\" fill=\"#fff\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">Stage 1<\/text>\n      <text x=\"80\" y=\"72\" text-anchor=\"middle\" fill=\"rgba(255,255,255,0.85)\" font-size=\"7\" font-family=\"Georgia,serif\">Asymptomatic<\/text>\n      <text x=\"80\" y=\"100\" text-anchor=\"middle\" fill=\"#3D5A80\" font-size=\"7.5\" font-family=\"Georgia,serif\">Hyperuricaemia<\/text>\n      <text x=\"80\" y=\"110\" text-anchor=\"middle\" fill=\"#3D5A80\" font-size=\"7.5\" font-family=\"Georgia,serif\">no crystals yet<\/text>\n      <!-- Stage 2 -->\n      <circle cx=\"200\" cy=\"65\" r=\"22\" fill=\"#8B3D20\" opacity=\"0.85\"\/>\n      <text x=\"200\" y=\"61\" text-anchor=\"middle\" fill=\"#fff\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">Stage 2<\/text>\n      <text x=\"200\" y=\"72\" text-anchor=\"middle\" fill=\"rgba(255,255,255,0.85)\" font-size=\"7\" font-family=\"Georgia,serif\">Acute Gout<\/text>\n      <text x=\"200\" y=\"100\" text-anchor=\"middle\" fill=\"#8B3D20\" font-size=\"7.5\" font-family=\"Georgia,serif\">Acute MSU crystal<\/text>\n      <text x=\"200\" y=\"110\" text-anchor=\"middle\" fill=\"#8B3D20\" font-size=\"7.5\" font-family=\"Georgia,serif\">synovitis; MTP1<\/text>\n      <!-- Stage 3 -->\n      <circle cx=\"320\" cy=\"65\" r=\"22\" fill=\"#C07828\" opacity=\"0.85\"\/>\n      <text x=\"320\" y=\"61\" text-anchor=\"middle\" fill=\"#fff\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">Stage 3<\/text>\n      <text x=\"320\" y=\"72\" text-anchor=\"middle\" fill=\"rgba(255,255,255,0.85)\" font-size=\"7\" font-family=\"Georgia,serif\">Intercritical<\/text>\n      <text x=\"320\" y=\"100\" text-anchor=\"middle\" fill=\"#C07828\" font-size=\"7.5\" font-family=\"Georgia,serif\">Asymptomatic<\/text>\n      <text x=\"320\" y=\"110\" text-anchor=\"middle\" fill=\"#C07828\" font-size=\"7.5\" font-family=\"Georgia,serif\">intervals; ULT target<\/text>\n      <!-- Stage 4 -->\n      <circle cx=\"440\" cy=\"65\" r=\"22\" fill=\"#B83232\" opacity=\"0.85\"\/>\n      <text x=\"440\" y=\"61\" text-anchor=\"middle\" fill=\"#fff\" font-size=\"8\" font-family=\"Georgia,serif\" font-weight=\"bold\">Stage 4<\/text>\n      <text x=\"440\" y=\"72\" text-anchor=\"middle\" fill=\"rgba(255,255,255,0.85)\" font-size=\"7\" font-family=\"Georgia,serif\">Chronic Tophaceous<\/text>\n      <text x=\"440\" y=\"100\" text-anchor=\"middle\" fill=\"#B83232\" font-size=\"7.5\" font-family=\"Georgia,serif\">Tophi; chronic joint<\/text>\n      <text x=\"440\" y=\"110\" text-anchor=\"middle\" fill=\"#B83232\" font-size=\"7.5\" font-family=\"Georgia,serif\">destruction; nephropathy<\/text>\n      <!-- Arrows -->\n      <polygon points=\"108,61 120,65 108,69\" fill=\"#C8D8D4\"\/>\n      <polygon points=\"228,61 240,65 228,69\" fill=\"#C8D8D4\"\/>\n      <polygon points=\"348,61 360,65 348,69\" fill=\"#C8D8D4\"\/>\n      <!-- ULT target label -->\n      <rect x=\"270\" y=\"14\" width=\"100\" height=\"18\" rx=\"4\" fill=\"#2D6B47\" opacity=\"0.85\"\/>\n      <text x=\"320\" y=\"26\" text-anchor=\"middle\" fill=\"#fff\" font-size=\"8\" font-family=\"Georgia,serif\">ULT target: SUA &lt;6 mg\/dL<\/text>\n      <line x1=\"320\" y1=\"32\" x2=\"320\" y2=\"43\" stroke=\"#2D6B47\" stroke-width=\"1.5\" stroke-dasharray=\"3,2\"\/>\n    <\/svg>\n    <figcaption>\n      Four clinical stages of gout. <strong>Stage 2 (acute) is the presentation<\/strong>; ULT is initiated during the <strong>intercritical period (Stage 3)<\/strong>, not during an acute attack. Target serum uric acid: <strong>&lt;6 mg\/dL<\/strong> (360 &mu;mol\/L) for most patients; &lt;5 mg\/dL for tophaceous gout.\n    <\/figcaption>\n  <\/figure>\n<\/div>\n\n<div id=\"rhmq04\">\n\n  <div class=\"mr-header\">\n    <div class=\"mr-eyebrow\">Morning Rounds &middot; Rheumatology Series &middot; Round 04<\/div>\n    <div class=\"mr-title\">\n      Crystal Arthropathies<br><em>Clinical Reasoning<\/em>\n    <\/div>\n    <div class=\"mr-subtitle\">Five high-yield clinical cases &middot; +4 \/ &minus;1 scoring &middot; NEET-PG and UPSC CMS<\/div>\n    <div class=\"mr-chips\">\n      <span class=\"mr-chip\">5 Cases<\/span>\n      <span class=\"mr-chip\">+4 \/ &minus;1 scoring<\/span>\n      <span class=\"mr-chip\">Options reshuffled<\/span>\n    <\/div>\n  <\/div>\n\n  <div class=\"mr-sentinel\" id=\"rhmq04-sentinel\"><\/div>\n\n  <div class=\"mr-progress\" id=\"rhmq04-progress\">\n    <div class=\"mr-prog-inner\">\n      <div class=\"mr-pips\" id=\"rhmq04-pips\"><\/div>\n    <\/div>\n  <\/div>\n\n  <div class=\"mr-body\">\n    <div id=\"rhmq04-cases\"><\/div>\n    <div class=\"mr-submit-wrap\">\n      <button class=\"mr-btn\" id=\"rhmq04-submit\">Submit for Debrief<\/button>\n    <\/div>\n    <div class=\"mr-score\" id=\"rhmq04-score\">\n      <div class=\"mr-score-in\">\n        <div class=\"mr-score-ey\">Round Complete<\/div>\n        <div class=\"mr-ring\" id=\"rhmq04-ring\">\n          <div class=\"mr-ring-in\">\n            <span class=\"mr-ring-pct\" id=\"rhmq04-pct\">0%<\/span>\n            <span class=\"mr-ring-sub\">net<\/span>\n          <\/div>\n        <\/div>\n        <div class=\"mr-score-title\">Your Debrief<\/div>\n        <div class=\"mr-score-net\" id=\"rhmq04-net\"><\/div>\n        <div class=\"mr-verdict\" id=\"rhmq04-verdict\"><\/div>\n        <div class=\"mr-bands\">\n          <span class=\"mr-band mr-band-c\" id=\"rhmq04-ct-c\"><\/span>\n          <span class=\"mr-band mr-band-w\" id=\"rhmq04-ct-w\"><\/span>\n          <span class=\"mr-band mr-band-s\" id=\"rhmq04-ct-s\"><\/span>\n        <\/div>\n        <button class=\"mr-retry\" id=\"rhmq04-retry\">&#8635; New Round<\/button>\n      <\/div>\n    <\/div>\n  <\/div>\n\n<\/div><!-- end #rhmq04 -->\n\n<script>\n(function () {\n  'use strict';\n\n  var NS    = 'rhmq04';\n  var TOTAL = 5;\n  var MAX   = 20;\n  var LTRS  = ['A','B','C','D'];\n\n  var QS = [\n\n    \/* ---- Q1 : Gout \u2014 Synovial Fluid & Diagnosis (avoids birefringence \u2014 covered in Round 01) ---- *\/\n    {\n      id:   1,\n      diff: 'Easy',\n      tag:  'Gout &mdash; Diagnosis &amp; Synovial Fluid',\n      stem: 'A <strong>52-year-old man<\/strong> with hypertension and type 2 diabetes presents with an <strong>acutely swollen, hot, erythematous right knee<\/strong> of 18 hours duration. He is on ramipril, metformin, and low-dose aspirin. Temperature is 38.2&deg;C. Serum uric acid (SUA) is <strong>5.8 mg\/dL<\/strong>. Synovial fluid aspirated from the right knee has WBC 38,000\/mm&sup3; (90% neutrophils) and is examined under compensated polarised light microscopy. Which statement regarding his SUA and the synovial fluid findings is <em>most accurate<\/em>?',\n      correct: 'A normal serum uric acid does not exclude gout; SUA falls during an acute attack due to uricosuric effects of ACTH and cytokines; the synovial WBC of 38,000 with neutrophil predominance is consistent with crystal arthritis but does not exclude septic arthritis',\n      opts: [\n        'A normal serum uric acid does not exclude gout; SUA falls during an acute attack due to uricosuric effects of ACTH and cytokines; the synovial WBC of 38,000 with neutrophil predominance is consistent with crystal arthritis but does not exclude septic arthritis',\n        'A serum uric acid of 5.8 mg\/dL is within normal range and definitively excludes gout as the diagnosis; the fever and neutrophil-predominant synovial fluid confirm septic arthritis requiring immediate IV antibiotics',\n        'Synovial fluid WBC &gt;20,000\/mm&sup3; with neutrophil predominance is diagnostic of septic arthritis; crystal arthritis never produces a WBC above 20,000 and empirical antibiotics must be started before crystal microscopy results',\n        'Low-dose aspirin is uricosuric and lowers serum uric acid; the normal SUA therefore confirms that his aspirin therapy has been therapeutic and gout is unlikely in a well-controlled patient'\n      ],\n      exp:  'A <strong>normal or low SUA does not exclude gout<\/strong>. During an acute attack, interleukin-6 and ACTH stimulate renal urate excretion, causing SUA to fall transiently \u2014 often into the normal range. SUA should be rechecked 4&ndash;6 weeks after the attack resolves. Synovial WBC in gout ranges from 5,000 to 60,000\/mm&sup3; (neutrophil-predominant), overlapping with septic arthritis. A WBC &gt;50,000 strongly suggests infection but does not exclude crystals; <strong>both can coexist<\/strong>. Gram stain and culture must always be sent. <strong>Low-dose aspirin<\/strong> (&lt;2 g\/day) is actually <em>urate-retaining<\/em> (blocks tubular secretion); high-dose aspirin (&gt;3 g\/day) is uricosuric. This patient&rsquo;s aspirin is therefore a precipitating factor, not protective.',\n      extra: '<strong>ACR 2015 Gout Classification Criteria<\/strong>: used when synovial fluid crystal identification is not available. Scored across three domains &mdash; clinical (joint involvement pattern, symptom characteristics, time course), laboratory (SUA, synovial WBC), and imaging (double contour sign on USS, urate deposition on DECT, erosions on X-ray). Score &ge;8 = classified as gout. <strong>Dual-energy CT (DECT)<\/strong>: colour-codes urate deposits (green) vs calcium (blue) based on differential X-ray attenuation; highly sensitive for tophaceous deposits but expensive and not yet routine in India. <strong>Ultrasound double contour sign<\/strong>: hyperechoic line over the superficial aspect of articular cartilage (MSU crystals deposited on cartilage surface) \u2014 highly specific for gout.',\n      imgId: null\n    },\n\n    \/* ---- Q2 : Gout \u2014 ULT Timing & Targets ---- *\/\n    {\n      id:   2,\n      diff: 'Medium',\n      tag:  'Gout &mdash; Urate-Lowering Therapy',\n      stem: 'A <strong>58-year-old man<\/strong> has had <strong>four acute gout attacks in the past 18 months<\/strong>, affecting his right MTP joint, left ankle, and right knee sequentially. Examination reveals <strong>two small tophi<\/strong> over the right olecranon and left Achilles tendon. SUA between attacks is consistently 9.2 mg\/dL. His physician correctly initiates allopurinol. He asks several questions about his treatment. Which combination of statements regarding urate-lowering therapy (ULT) in his case is <em>most accurate<\/em>?',\n      correct: 'ULT should be started 2&ndash;4 weeks after the acute attack has fully resolved, not during the attack; allopurinol should be started at a low dose (50&ndash;100 mg\/day) and titrated slowly; prophylactic colchicine or NSAID should be co-prescribed for the first 3&ndash;6 months to prevent mobilisation flares',\n      opts: [\n        'ULT should be started 2&ndash;4 weeks after the acute attack has fully resolved, not during the attack; allopurinol should be started at a low dose (50&ndash;100 mg\/day) and titrated slowly; prophylactic colchicine or NSAID should be co-prescribed for the first 3&ndash;6 months to prevent mobilisation flares',\n        'ULT should be started immediately during an acute attack to lower SUA rapidly and shorten the attack duration; allopurinol at full therapeutic dose (300 mg\/day) from day one minimises the risk of subsequent attacks',\n        'Since this patient has tophi, ULT is contraindicated until tophi are surgically debrided; tophaceous deposits are insoluble and will not respond to ULT-mediated SUA reduction',\n        'Prophylactic colchicine is unnecessary once allopurinol is started because the mechanism of allopurinol (xanthine oxidase inhibition) prevents crystal formation from the first dose; mobilisation flares only occur with uricosuric agents such as probenecid'\n      ],\n      exp:  'Initiation of ULT <strong>during<\/strong> an acute attack can prolong or precipitate new attacks by causing rapid crystal mobilisation. The standard recommendation is to begin ULT <strong>2&ndash;4 weeks after full resolution<\/strong> of the acute attack (though recent RCT evidence suggests starting during the attack is not harmful if initiated with adequate flare prophylaxis). <strong>Allopurinol<\/strong> (xanthine oxidase inhibitor) is started at 50&ndash;100 mg\/day and titrated up in 50&ndash;100 mg increments every 2&ndash;4 weeks to achieve the SUA target of <strong>&lt;6 mg\/dL<\/strong> (&lt;5 mg\/dL for tophaceous gout). <strong>Mobilisation flares<\/strong> occur because falling SUA destabilises existing crystal deposits \u2014 tophi dissolve and shed crystals into the joint. <strong>Prophylactic low-dose colchicine<\/strong> (0.5&ndash;1 mg\/day) or NSAID is co-prescribed for the first <strong>3&ndash;6 months<\/strong> of ULT to cover this vulnerable period.',\n      extra: '<strong>Febuxostat<\/strong>: a selective non-purine xanthine oxidase inhibitor. Advantages over allopurinol: no dose adjustment needed in mild-to-moderate CKD; can be used in allopurinol-intolerant patients. Disadvantages: more expensive; CARES trial raised concern about cardiovascular mortality (subsequently disputed). <strong>Allopurinol hypersensitivity syndrome (AHS)<\/strong>: rare but severe \u2014 fever, rash (Stevens-Johnson syndrome), hepatitis, renal failure, eosinophilia. Strongly associated with <strong>HLA-B*5801<\/strong> \u2014 particularly prevalent in Han Chinese, Thai, and Korean populations. CPIC guidelines recommend HLA-B*5801 screening before allopurinol initiation in these populations. <strong>Probenecid<\/strong>: uricosuric agent; contraindicated in urolithiasis and CKD (GFR &lt;30); not effective in overproducers. Mechanism: blocks URAT1 transporter in proximal tubule.',\n      imgId: 'rhmq04-img1'\n    },\n\n    \/* ---- Q3 : CPPD \u2014 Pseudogout vs Gout ---- *\/\n    {\n      id:   3,\n      diff: 'Medium',\n      tag:  'CPPD &mdash; Pseudogout',\n      stem: 'An <strong>82-year-old woman<\/strong> is brought in with an <strong>acutely swollen, warm right knee<\/strong> of 24 hours duration. She has no history of gout. Her medications include levothyroxine, amlodipine, and furosemide. Knee X-ray shows <strong>chondrocalcinosis<\/strong> of the medial and lateral menisci and articular cartilage. SUA is 4.2 mg\/dL. Synovial fluid shows WBC 24,000\/mm&sup3; with 85% neutrophils; no organisms on Gram stain. Crystals are identified under compensated polarised light. Which combination of findings on crystal analysis and associated metabolic condition is <em>most accurate<\/em> for this patient?',\n      correct: 'CPPD crystals are rhomboid-shaped and weakly positively birefringent; hypothyroidism (for which she takes levothyroxine) is a recognised metabolic precipitant of CPPD deposition disease',\n      opts: [\n        'CPPD crystals are rhomboid-shaped and weakly positively birefringent; hypothyroidism (for which she takes levothyroxine) is a recognised metabolic precipitant of CPPD deposition disease',\n        'CPPD crystals are needle-shaped and negatively birefringent, identical to MSU crystals but distinguished by their rhomboid ends; furosemide is the specific precipitant of CPPD deposition through its effect on calcium transport',\n        'Chondrocalcinosis on X-ray is diagnostic of CPPD and no further synovial fluid analysis is required; the metabolic workup in a patient over 80 years is unnecessary as idiopathic CPPD is the default diagnosis at this age',\n        'The weakly positive birefringence of CPPD means the crystals appear yellow when perpendicular to the slow axis and blue when parallel &mdash; the exact inverse of the rule applied to MSU crystals under the same optical conditions'\n      ],\n      exp:  '<strong>CPPD crystals (calcium pyrophosphate dihydrate)<\/strong> are <strong>rhomboid<\/strong> (or rod-shaped) and exhibit <strong>weak positive birefringence<\/strong> &mdash; they appear <em>blue<\/em> when parallel to the compensator slow axis and yellow when perpendicular (the opposite of MSU). Chondrocalcinosis on X-ray (calcification of fibrocartilage: menisci, triangular fibrocartilage of wrist, symphysis pubis) supports the diagnosis but is not pathognomonic &mdash; calcium hydroxyapatite can also calcify articular cartilage. <strong>Metabolic precipitants of CPPD<\/strong>: the mnemonic <em>HATCH<\/em> &mdash; Hyperparathyroidism, Ageing (most common), hypothyroidism (Thyroid), CPPD familial (Chondrocalcinosis hereditary), Haemochromatosis, hypomagnesaemia, hypophosphataemia. Furosemide causes hypomagnesaemia (renal Mg wasting) &mdash; a less prominent but valid association.',\n      extra: '<strong>CPPD disease spectrum<\/strong> (four presentations): (1) <em>Asymptomatic chondrocalcinosis<\/em> &mdash; incidental X-ray finding; (2) <em>Acute CPP crystal arthritis (pseudogout)<\/em> &mdash; sudden, self-limiting monoarthritis; knee most common (vs MTP1 in gout); (3) <em>Chronic CPP crystal inflammatory arthritis<\/em> &mdash; mimics RA; symmetrical small joint involvement; (4) <em>Osteoarthritis with CPPD<\/em> &mdash; accelerated OA at atypical sites (wrist, MCP, shoulder). <strong>Crowned dens syndrome<\/strong>: CPPD deposition around the odontoid process of C2 causes severe neck pain, fever, and elevated CRP &mdash; mimics meningitis. CT neck shows calcification around the dens. Treated with NSAIDs or colchicine. <strong>Treatment of acute pseudogout<\/strong>: NSAIDs, colchicine, or intra-articular corticosteroids (same as gout). No urate-lowering equivalent exists for CPPD &mdash; there is no proven agent to dissolve pyrophosphate deposits.',\n      imgId: null\n    },\n\n    \/* ---- Q4 : Gout \u2014 CKD & Drug Interactions ---- *\/\n    {\n      id:   4,\n      diff: 'Hard',\n      tag:  'Gout &mdash; CKD &amp; Drug Interactions',\n      stem: 'A <strong>64-year-old man<\/strong> with <strong>stage 3b CKD (eGFR 32 mL\/min)<\/strong>, hypertension, and recurrent gout (three attacks in 12 months, no tophi) presents during an acute attack of his right ankle. His medications include amlodipine, losartan, and allopurinol 100 mg\/day. His SUA between attacks is 8.4 mg\/dL despite allopurinol. His rheumatologist considers escalating his gout management. Which combination of statements regarding management in this context is <em>most correct<\/em>?',\n      correct: 'Allopurinol can be cautiously uptitrated above 100 mg\/day in CKD if tolerated and monitored; losartan has a mild uricosuric effect and is a preferred antihypertensive in gout; colchicine dose must be reduced in CKD (eGFR &lt;30) and NSAIDs should be avoided',\n      opts: [\n        'Allopurinol can be cautiously uptitrated above 100 mg\/day in CKD if tolerated and monitored; losartan has a mild uricosuric effect and is a preferred antihypertensive in gout; colchicine dose must be reduced in CKD (eGFR &lt;30) and NSAIDs should be avoided',\n        'Allopurinol must be strictly dose-capped at 100 mg\/day for any patient with eGFR &lt;60 and should never be increased regardless of SUA levels; febuxostat is absolutely contraindicated in all stages of CKD',\n        'NSAIDs are the treatment of choice for acute gout in CKD as colchicine accumulates in renal failure and causes fatal toxicity even at standard doses; short-course NSAIDs for 3&ndash;5 days do not affect renal function in stable CKD',\n        'Losartan should be replaced with a calcium channel blocker in this patient as ARBs worsen hyperuricaemia through tubular uric acid retention; amlodipine has no effect on serum uric acid and is the preferred antihypertensive in gout'\n      ],\n      exp:  'Traditional guidelines capped allopurinol dosing in CKD (based on creatinine clearance) but contemporary evidence shows this approach is the primary reason for <strong>undertreated gout in CKD<\/strong>. The 2020 ACR Gout Guidelines recommend <strong>cautious uptitration of allopurinol<\/strong> even in CKD, with close monitoring for hypersensitivity. <strong>Febuxostat<\/strong> requires no dose adjustment for mild-to-moderate CKD and is a valid alternative. <strong>Losartan<\/strong> is the only ARB with a clinically meaningful uricosuric effect (blocks URAT1) &mdash; making it the preferred antihypertensive agent in gouty patients with hypertension. <strong>NSAIDs<\/strong> are nephrotoxic (reduce renal prostaglandin synthesis) and should be <strong>avoided in CKD eGFR &lt;30<\/strong>. <strong>Colchicine<\/strong> accumulates in renal failure &mdash; at eGFR &lt;30, dose is reduced to 0.5 mg once daily and repeat dosing within 14 days is avoided.',\n      extra: '<strong>Drugs that raise serum uric acid<\/strong> (high-yield list): Diuretics &mdash; thiazides and loop diuretics (reduce renal urate excretion); Low-dose aspirin (&lt;2 g\/day); Ciclosporin; Tacrolimus; Pyrazinamide; Ethambutol; Nicotinic acid; Levodopa. <strong>Drugs that lower serum uric acid<\/strong>: Losartan; Fenofibrate; SGLT2 inhibitors (empagliflozin, dapagliflozin &mdash; increasingly used in CKD\/heart failure patients; the uricosuric effect is a useful secondary benefit); High-dose aspirin (&gt;3 g\/day). <strong>SGLT2 inhibitors in gout<\/strong>: a clinically important emerging area &mdash; in patients with CKD, heart failure, or T2DM who also have gout, an SGLT2 inhibitor may partially fulfil the uricosuric role, allowing lower allopurinol doses. Not yet a standard gout treatment but examiners have started testing this.',\n      imgId: null\n    },\n\n    \/* ---- Q5 : Calcium Hydroxyapatite & Differentials ---- *\/\n    {\n      id:   5,\n      diff: 'Hard',\n      tag:  'Calcium Hydroxyapatite &mdash; Milwaukee Shoulder',\n      stem: 'A <strong>74-year-old woman<\/strong> presents with a <strong>3-month history of progressive right shoulder pain and marked weakness<\/strong>. Examination reveals a <strong>large, cool, non-tender right shoulder effusion<\/strong> with wasting of the supraspinatus and infraspinatus. There is no fever. Plain X-ray of the right shoulder shows <strong>dense calcific deposits<\/strong> in the supraspinatus tendon and marked destruction of the glenohumeral joint with superior migration of the humeral head. Synovial fluid is blood-tinged; WBC 1,200\/mm&sup3;. No crystals are identified on standard polarised light microscopy. Which diagnosis and key diagnostic finding best explains this presentation?',\n      correct: 'Milwaukee shoulder syndrome (basic calcium phosphate\/hydroxyapatite deposition disease); hydroxyapatite crystals are not birefringent and are not visible on standard polarised light microscopy &mdash; they require alizarin red S staining or electron microscopy for identification',\n      opts: [\n        'Milwaukee shoulder syndrome (basic calcium phosphate\/hydroxyapatite deposition disease); hydroxyapatite crystals are not birefringent and are not visible on standard polarised light microscopy &mdash; they require alizarin red S staining or electron microscopy for identification',\n        'Septic arthritis of the shoulder with concurrent rotator cuff tear; the low synovial WBC excludes infection but the blood-tinged fluid indicates haemarthrosis from an underlying coagulopathy requiring factor replacement',\n        'CPPD arthropathy (pseudogout) of the shoulder; the failure to identify crystals on polarised light microscopy indicates the synovial fluid sample was inadequate; repeat aspiration with immediate processing will reveal the characteristic rhomboid crystals',\n        'Neuropathic (Charcot) arthropathy of the shoulder from syringomyelia; the calcific tendon deposits and joint destruction are typical of neurogenic joint disease and are not caused by crystal deposition'\n      ],\n      exp:  '<strong>Milwaukee shoulder syndrome<\/strong> is caused by <strong>basic calcium phosphate (BCP) \/ hydroxyapatite crystal deposition<\/strong> in the rotator cuff and glenohumeral joint. It typically affects elderly women and causes a <strong>large, non-inflammatory effusion<\/strong> (low WBC, often blood-tinged due to concurrent rotator cuff tear) with progressive joint destruction &mdash; a destructive arthropathy. The hallmark is the triad of: (1) large shoulder effusion; (2) rotator cuff tear; (3) glenohumeral joint destruction with superior humeral head migration. <strong>Critically<\/strong>: hydroxyapatite crystals are <em>not birefringent<\/em> and are <strong>invisible on standard polarised light microscopy<\/strong>. They appear as shiny &ldquo;coins&rdquo; on plain light microscopy and are confirmed by <strong>alizarin red S stain<\/strong> (stains calcium-containing crystals red) or transmission electron microscopy with electron-dispersive spectroscopy.',\n      extra: '<strong>Crystal arthropathy comparison &mdash; exam summary table:<\/strong><br>MSU (Gout): needle-shaped; negative birefringence; yellow parallel to slow axis; MTP1 most common joint; associated with hyperuricaemia, thiazides, low-dose aspirin.<br>CPPD (Pseudogout): rhomboid; weak positive birefringence; blue parallel to slow axis; knee most common; associated with HATCH metabolic conditions; chondrocalcinosis on X-ray.<br>BCP\/Hydroxyapatite (Milwaukee): not birefringent; invisible on polarised light; shoulder (rotator cuff); large non-inflammatory effusion; alizarin red S stain; elderly women.<br><strong>Haemarthrosis differentials<\/strong> (blood-tinged synovial fluid): trauma; haemophilia; anticoagulation; pigmented villonodular synovitis (PVNS); Charcot joint; Milwaukee shoulder. A non-inflammatory WBC (&lt;2,000) with blood-tinged fluid in an elderly woman with shoulder destruction is Milwaukee until proven otherwise.'\n    }\n\n  ];\n\n  var answers  = {};\n  var answered = 0;\n  var shuffled = {};\n  var done     = false;\n\n  function byId(id) { return document.getElementById(id); }\n  function gid(sfx) { return byId(NS + '-' + sfx); }\n\n  function shuffleArr(arr) {\n    var a = arr.slice(), i, j, t;\n    for (i = a.length - 1; i > 0; i--) {\n      j = Math.floor(Math.random() * (i + 1));\n      t = a[i]; a[i] = a[j]; a[j] = t;\n    }\n    return a;\n  }\n\n  function countVal(val) {\n    var k, n = 0;\n    for (k in answers) {\n      if (answers.hasOwnProperty(k) && answers[k] === val) n++;\n    }\n    return n;\n  }\n\n  function buildPips() {\n    var cont = gid('pips'), i, q, wl, wp, line, pip;\n    if (!cont) return;\n    cont.innerHTML = '';\n    for (i = 0; i < QS.length; i++) {\n      q = QS[i];\n      if (i > 0) {\n        wl = document.createElement('div'); wl.className = 'mr-pip-wrap';\n        line = document.createElement('div'); line.className = 'mr-pip-line';\n        line.id = NS + '-pl' + q.id;\n        wl.appendChild(line); cont.appendChild(wl);\n      }\n      wp  = document.createElement('div'); wp.className = 'mr-pip-wrap';\n      pip = document.createElement('div'); pip.className = 'mr-pip';\n      pip.id = NS + '-pip' + q.id;\n      pip.textContent = String(q.id);\n      wp.appendChild(pip); cont.appendChild(wp);\n    }\n  }\n\n  function build() {\n    var cont, i, q, opts, card, top, nd, meta, tagRow, tg, dl,\n        st, rule, od, ed, lb, tx, ep, epl, ept, imgSrc, imgDiv, j, oe, ls, ts;\n    cont = gid('cases');\n    if (!cont) return;\n    cont.innerHTML = '';\n    answers = {}; answered = 0; shuffled = {}; done = false;\n    if (gid('score')) gid('score').style.display = 'none';\n    buildPips();\n\n    for (i = 0; i < QS.length; i++) {\n      q    = QS[i];\n      opts = shuffleArr(q.opts);\n      shuffled[q.id] = opts;\n\n      card = document.createElement('div'); card.className = 'mr-case';\n      top  = document.createElement('div'); top.className  = 'mr-case-top';\n      nd   = document.createElement('div'); nd.className   = 'mr-num';\n      nd.textContent = q.id < 10 ? '0' + q.id : String(q.id);\n      meta = document.createElement('div'); meta.className = 'mr-meta';\n\n      tagRow = document.createElement('div'); tagRow.className = 'mr-tag-row';\n      tg = document.createElement('div'); tg.className = 'mr-tag'; tg.innerHTML = q.tag;\n      dl = document.createElement('div'); dl.className = 'mr-diff'; dl.textContent = q.diff;\n      tagRow.appendChild(tg); tagRow.appendChild(dl);\n\n      st = document.createElement('div'); st.className = 'mr-stem'; st.innerHTML = q.stem;\n      meta.appendChild(tagRow); meta.appendChild(st);\n      top.appendChild(nd); top.appendChild(meta);\n      card.appendChild(top);\n\n      rule = document.createElement('div'); rule.className = 'mr-rule';\n      card.appendChild(rule);\n\n      od = document.createElement('div'); od.className = 'mr-opts';\n      for (j = 0; j < opts.length; j++) {\n        oe = document.createElement('div'); oe.className = 'mr-opt';\n        oe.id = NS + '-o' + q.id + '-' + j;\n        oe.setAttribute('role', 'button'); oe.setAttribute('tabindex', '0');\n        ls = document.createElement('span'); ls.className = 'mr-ltr'; ls.textContent = LTRS[j];\n        ts = document.createElement('span'); ts.className = 'mr-opt-text'; ts.innerHTML = opts[j];\n        oe.appendChild(ls); oe.appendChild(ts); od.appendChild(oe);\n        (function (qid, oi) {\n          oe.addEventListener('click', function () { pick(qid, oi); });\n        }(q.id, j));\n      }\n      card.appendChild(od);\n\n      ed  = document.createElement('div'); ed.className = 'mr-exp'; ed.id = NS + '-exp' + q.id;\n      lb  = document.createElement('div'); lb.className = 'mr-exp-lbl'; lb.textContent = 'Debrief';\n      tx  = document.createElement('div'); tx.className = 'mr-exp-text'; tx.innerHTML = q.exp;\n      ed.appendChild(lb); ed.appendChild(tx);\n\n      if (q.imgId) {\n        imgSrc = byId(q.imgId);\n        if (imgSrc) {\n          imgDiv = document.createElement('div');\n          imgDiv.innerHTML = imgSrc.innerHTML;\n          ed.appendChild(imgDiv);\n        }\n      }\n\n      if (q.extra) {\n        ep  = document.createElement('div'); ep.className = 'mr-exp-extra';\n        epl = document.createElement('span'); epl.className = 'mr-exp-extra-lbl'; epl.textContent = 'Extra Points';\n        ept = document.createElement('div'); ept.innerHTML = q.extra;\n        ep.appendChild(epl); ep.appendChild(ept);\n        ed.appendChild(ep);\n      }\n\n      card.appendChild(ed);\n      cont.appendChild(card);\n    }\n  }\n\n  function pick(qid, oi) {\n    var q, opts, i, el, ok;\n    if (answers[qid] !== undefined || done) return;\n    q = null;\n    for (i = 0; i < QS.length; i++) { if (QS[i].id === qid) { q = QS[i]; break; } }\n    if (!q) return;\n    opts = shuffled[qid];\n    ok   = (opts[oi] === q.correct);\n    answers[qid] = ok ? 'c' : 'w';\n    answered++;\n    for (i = 0; i < opts.length; i++) {\n      el = byId(NS + '-o' + qid + '-' + i);\n      if (!el) continue;\n      el.className = opts[i] === q.correct ? 'mr-opt correct locked'\n                   : i === oi              ? 'mr-opt wrong locked'\n                                           : 'mr-opt dimmed locked';\n    }\n    var ex = byId(NS + '-exp' + qid); if (ex) ex.style.display = 'block';\n    var pp = byId(NS + '-pip' + qid); if (pp) pp.className = 'mr-pip ' + (ok ? 'correct' : 'wrong');\n    if (qid > 1) { var pl = gid('pl' + qid); if (pl) pl.className = 'mr-pip-line done'; }\n  }\n\n  function showScore() {\n    var c, w, s, net, pct, disp, vlist, vi, sc;\n    if (done) return;\n    done = true;\n    c   = countVal('c'); w = countVal('w'); s = TOTAL - answered;\n    net  = c * 4 - w;\n    pct  = Math.max(0, Math.round((net \/ MAX) * 100));\n    disp = Math.min(100, Math.max(0, pct));\n    var rg = gid('ring');\n    if (rg) rg.style.background = 'conic-gradient(#8B3D20 ' + disp + '%, #E8DDD8 0%)';\n    var pe = gid('pct'); if (pe) pe.textContent = pct + '%';\n    var ne = gid('net'); if (ne) ne.textContent = 'Net Score: ' + net + ' \/ ' + MAX;\n    vlist = [\n      [5, 'Flawless. Every crystal, every drug interaction \\u2014 nothing escaped you.'],\n      [4, 'Strong \\u2014 one nuance worth revisiting before exam day.'],\n      [3, 'Solid base \\u2014 the Extra Points carry the clinical edge here.'],\n      [2, 'Halfway \\u2014 the CKD-gout interactions and Milwaukee shoulder repay close reading.'],\n      [0, 'Crystal arthropathies reward careful comparison. The debrief panels have everything \\u2014 one more pass will make it click.']\n    ];\n    var ve = gid('verdict');\n    if (ve) {\n      ve.textContent = vlist[4][1];\n      for (vi = 0; vi < vlist.length; vi++) {\n        if (c >= vlist[vi][0]) { ve.textContent = vlist[vi][1]; break; }\n      }\n    }\n    var cc = gid('ct-c'); if (cc) cc.textContent = '\\u2705 ' + c + ' Correct';\n    var cw = gid('ct-w'); if (cw) cw.textContent = '\\u274C ' + w + ' Wrong';\n    var cs = gid('ct-s'); if (cs) cs.textContent = '\\u23ED ' + s + ' Skipped';\n    sc = gid('score');\n    if (sc) { sc.style.display = 'block'; sc.scrollIntoView({ behavior: 'smooth', block: 'center' }); }\n  }\n\n  function initObserver() {\n    var sn = gid('sentinel'), bar = gid('progress');\n    if (!sn || !bar || !window.IntersectionObserver) return;\n    new IntersectionObserver(function (en) {\n      bar.className = en[0].isIntersecting ? 'mr-progress' : 'mr-progress visible';\n    }, { threshold: 0 }).observe(sn);\n  }\n\n  function init() {\n    var sb = gid('submit'), rb = gid('retry');\n    if (!sb || !rb) return;\n    sb.addEventListener('click', showScore);\n    rb.addEventListener('click', function () { build(); window.scrollTo(0, 0); });\n    initObserver();\n    build();\n  }\n\n  function tryInit(n) {\n    if (document.getElementById('rhmq04-cases')) {\n      init();\n    } else if (n < 40) {\n      setTimeout(function () { tryInit(n + 1); }, 50);\n    }\n  }\n\n  tryInit(0);\n\n}());\n<\/script>\n\n\n","protected":false},"excerpt":{"rendered":"<p>Morning Rounds \u00b7 Crystal Arthropathies Stage 1 Asymptomatic Hyperuricaemia no crystals yet Stage 2 Acute Gout Acute MSU crystal synovitis; MTP1 Stage 3 Intercritical Asymptomatic intervals; ULT target Stage 4 Chronic Tophaceous Tophi; chronic joint destruction; nephropathy ULT target: SUA &lt;6 mg\/dL Four clinical stages of gout. Stage 2 (acute) is the presentation; ULT is&hellip;&nbsp;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"categories":[74,24,64],"tags":[],"class_list":["post-36952","post","type-post","status-publish","format-standard","hentry","category-morning-rounds","category-neet-pg","category-orthopaedics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Crystal Arthropathies - atsixty<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crystal Arthropathies - atsixty\" \/>\n<meta property=\"og:description\" content=\"Morning Rounds \u00b7 Crystal Arthropathies Stage 1 Asymptomatic Hyperuricaemia no crystals yet Stage 2 Acute Gout Acute MSU crystal synovitis; MTP1 Stage 3 Intercritical Asymptomatic intervals; ULT target Stage 4 Chronic Tophaceous Tophi; chronic joint destruction; nephropathy ULT target: SUA &lt;6 mg\/dL Four clinical stages of gout. Stage 2 (acute) is the presentation; ULT is&hellip;&nbsp;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/\" \/>\n<meta property=\"og:site_name\" content=\"atsixty\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-06T03:36:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-06T03:36:29+00:00\" \/>\n<meta name=\"author\" content=\"Avi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Avi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/crystal-arthropathies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/crystal-arthropathies\\\/\"},\"author\":{\"name\":\"Avi\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"headline\":\"Crystal Arthropathies\",\"datePublished\":\"2026-06-06T03:36:00+00:00\",\"dateModified\":\"2026-06-06T03:36:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/crystal-arthropathies\\\/\"},\"wordCount\":120,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"articleSection\":[\"Morning Rounds\",\"NEET PG\",\"Orthopaedics\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/crystal-arthropathies\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/crystal-arthropathies\\\/\",\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/crystal-arthropathies\\\/\",\"name\":\"Crystal Arthropathies - atsixty\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\"},\"datePublished\":\"2026-06-06T03:36:00+00:00\",\"dateModified\":\"2026-06-06T03:36:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/crystal-arthropathies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/crystal-arthropathies\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/neet-pg\\\/crystal-arthropathies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/atsixty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crystal Arthropathies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/#website\",\"url\":\"https:\\\/\\\/atsixty.com\\\/\",\"name\":\"At Sixty\",\"description\":\"The Option Taken\",\"publisher\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atsixty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/atsixty.com\\\/#\\\/schema\\\/person\\\/cf65e7ac7d8226d95c0bdf1036f7951d\",\"name\":\"Avi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"url\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"contentUrl\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\",\"width\":200,\"height\":200,\"caption\":\"Avi\"},\"logo\":{\"@id\":\"https:\\\/\\\/atsixty.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/logo-agency.png\"},\"sameAs\":[\"https:\\\/\\\/atsixty.com\"],\"url\":\"https:\\\/\\\/atsixty.com\\\/index.php\\\/author\\\/avinaux\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crystal Arthropathies - atsixty","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/","og_locale":"en_US","og_type":"article","og_title":"Crystal Arthropathies - atsixty","og_description":"Morning Rounds \u00b7 Crystal Arthropathies Stage 1 Asymptomatic Hyperuricaemia no crystals yet Stage 2 Acute Gout Acute MSU crystal synovitis; MTP1 Stage 3 Intercritical Asymptomatic intervals; ULT target Stage 4 Chronic Tophaceous Tophi; chronic joint destruction; nephropathy ULT target: SUA &lt;6 mg\/dL Four clinical stages of gout. Stage 2 (acute) is the presentation; ULT is&hellip;&nbsp;","og_url":"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/","og_site_name":"atsixty","article_published_time":"2026-06-06T03:36:00+00:00","article_modified_time":"2026-06-06T03:36:29+00:00","author":"Avi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Avi","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/#article","isPartOf":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/"},"author":{"name":"Avi","@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"headline":"Crystal Arthropathies","datePublished":"2026-06-06T03:36:00+00:00","dateModified":"2026-06-06T03:36:29+00:00","mainEntityOfPage":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/"},"wordCount":120,"commentCount":0,"publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"articleSection":["Morning Rounds","NEET PG","Orthopaedics"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/","url":"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/","name":"Crystal Arthropathies - atsixty","isPartOf":{"@id":"https:\/\/atsixty.com\/#website"},"datePublished":"2026-06-06T03:36:00+00:00","dateModified":"2026-06-06T03:36:29+00:00","breadcrumb":{"@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/atsixty.com\/index.php\/neet-pg\/crystal-arthropathies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/atsixty.com\/"},{"@type":"ListItem","position":2,"name":"Crystal Arthropathies"}]},{"@type":"WebSite","@id":"https:\/\/atsixty.com\/#website","url":"https:\/\/atsixty.com\/","name":"At Sixty","description":"The Option Taken","publisher":{"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atsixty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/atsixty.com\/#\/schema\/person\/cf65e7ac7d8226d95c0bdf1036f7951d","name":"Avi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","url":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","contentUrl":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png","width":200,"height":200,"caption":"Avi"},"logo":{"@id":"https:\/\/atsixty.com\/wp-content\/uploads\/2025\/08\/logo-agency.png"},"sameAs":["https:\/\/atsixty.com"],"url":"https:\/\/atsixty.com\/index.php\/author\/avinaux\/"}]}},"_links":{"self":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36952","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/comments?post=36952"}],"version-history":[{"count":1,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36952\/revisions"}],"predecessor-version":[{"id":36953,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/posts\/36952\/revisions\/36953"}],"wp:attachment":[{"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/media?parent=36952"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/categories?post=36952"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atsixty.com\/index.php\/wp-json\/wp\/v2\/tags?post=36952"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}